phCMV-GALV-MTR Citations (3)

Originally described in: Genetic modification of primary human B cells to model high-grade lymphoma.
Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, Cooke SL, Fenner R, Usheva Z, Runge HFP, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou GS, Huntly BJP, Mupo A, Bashford-Rogers RJM, Hodson DJ Nat Commun. 2019 Oct 4;10(1):4543. doi: 10.1038/s41467-019-12494-x. PubMed Journal

---

Articles Citing phCMV-GALV-MTR

Articles
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LW. Blood. 2022 Mar 3;139(9):1289-1301. doi: 10.1182/blood.2020008493. PubMed
Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. Bristol JA, Brand J, Ohashi M, Eichelberg MR, Casco A, Nelson SE, Hayes M, Romero-Masters JC, Baiu DC, Gumperz JE, Johannsen EC, Dinh HQ, Kenney SC. PLoS Pathog. 2022 Apr 26;18(4):e1010453. doi: 10.1371/journal.ppat.1010453. eCollection 2022 Apr. PubMed
BTG1 mutation yields supercompetitive B cells primed for malignant transformation. Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, Barisic D, Papin A, Hoehn KB, Kots E, Ersching J, Bandyopadhyay A, Barin E, Poh HX, Evans CM, Chadburn A, Chen Z, Shen H, Isles HM, Pelzer B, Tsialta I, Doane AS, Geng H, Rehman MH, Melnick J, Morgan W, Nguyen DTT, Elemento O, Kharas MG, Jaffrey SR, Scott DW, Khelashvili G, Meyer-Hermann M, Victora GD, Melnick A. Science. 2023 Jan 20;379(6629):eabj7412. doi: 10.1126/science.abj7412. Epub 2023 Jan 20. PubMed

If you have published an article using this material, please email us at to have your article added to this page.